secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115934
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q3 revenue $210.6M (+33% YoY), raises FY22 guidance to $810M-$830M
-------------------------------------------------------------------------

- Total revenues $210.6M, up 33% YoY; test volumes 517,500 (+27% YoY).
- Net loss $121.5M ($1.25/share) vs $151.3M ($1.63) in Q3 2021.
- Gross margin 44.7% vs 48.5% YoY due to labor/overhead costs; 2022 guidance raised by $40M.
- Oncology tests 53,000 (+153% YoY); Signatera pan-cancer contract with VA and Medicare IO monitoring set at $7,489.
- Board completes investigation, finds short seller allegations of wrongdoing unfounded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922115934/0001104659-22-115934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922115934/tm2229989d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer